



#1414J8  
7/25/01  
PATENT

Attorney Docket No: 28967/35255A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ferrell et al.

Serial No.: 09/375,248

Filed: August 16, 1999


For: Screening and Therapy for  
Lymphatic Disorders Involving the  
FLT4 Receptor Tyrosine Kinase  
(VEGFR-3)

Group Art Unit: 1633

Examiner: E. Sorbello

) I hereby certify that this paper is being  
) deposited with the United States Postal  
) Service with sufficient postage as first class  
) mail, postage prepaid, in an envelope  
) addressed to: Commissioner for Patents,  
) Washington, D.C. 20231 on this date:

) July 16, 2001

)   
) David A. Gass

) Reg. No. 38,153

) Attorney for Applicants

RECEIVED

JUL 23 2001

TECH CENTER 1600/2900

RESPONSE TO OFFICIAL ACTION UNDER 37 CFR 1.111

Commissioner for Patents  
Washington, DC 20231

Sir:

In an Official Action dated February 14, 2001, the Patent and Trademark Office rejected claims 1-11 and 14-21 of the above-identified patent application variously under 35 USC §§ 102, 103, and 112, first and second paragraphs. In light of the amendments and remarks presented below, Applicants request withdrawal of the rejections and favorable reconsideration of the application. This response is timely filed by virtue of a petition and fee for two months extension of time filed herewith, and by virtue of the fact that July 14 fell on a Saturday. No additional fees are believed to be due. However, should any fees be deemed necessary in connection with the filing of this document, the Commissioner is hereby authorized to deduct any such fees from Marshall O'Toole Gerstein Murray and Borun deposit account number 13-2855.